R&D tax credits were implemented in 1981 to reverse a dramatic decline in R&D and boost the economy. They don't work. It's time to end them. » Read More
Investors seeking steady gains on innovation should look past tech buzz. When R&D productivity is measured, 'boring' stocks often lead.
The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.
Using the CNBC RQ 50 measure for R&D productivity, we've identified an elite group of companies that merit election to an R&D hall of fame.
CNBC launches its first RQ 50 list, a predictive tool to find stocks with a highly competitive R&D growth and innovation strategy.
CNBC's Dominic Chu breaks down AMD and Intel to see which chip company is the most efficient allocator of research and developmental capital.
CNBC's Dominic Chu looks at how well Salix Pharmaceuticals and Vertex allocate spending on research and developmental capital.
CNBC's Dominic Chu looks at how well Lockheed Martin and Northrop Grumman allocate spending on research and developmental capital.
CNBC's Dominic Chu, breaks down Apple and Hewlett-Packard to see which company best optimizes R&D spending and creates the greatest shareholder value.
CNBC's Dominic Chu breaks down Mattel and Hasbro to see which company is the most efficient allocator of research and developmental capital.
CNBC's Dominic Chu, crunches the numbers to find out which company offers shareholders the greatest value.
The Edge explores the limitless potential of innovation.
A globe-trotting look at the world of investing, from developed Europe and Asia trends to the least-traveled frontier markets.
Take an in-depth look at the world of modern medicine - examining the treatments, companies and people making a difference in the way we treat illness and injuries today, and laying the foundation for the medical treatments of tomorrow.